Wedbush lifts Nabriva Therapeutics plc [NBRV] price estimate. Who else is bullish?

Related

Share

Nabriva Therapeutics plc [NASDAQ: NBRV] stock went on an upward path that rose over 20.73% on Thursday, amounting to a one-week price increase of more than 0.63%. The company report on December 22, 2021 that Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021.

— Meeting to Reconvene on January 14, 2022 —.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it intends to adjourn, without conducting any business, its extraordinary general meeting of shareholders (EGM), currently scheduled to take place on Wednesday, December 22, 2021, at 5:00 p.m. Irish time (12:00 p.m., U.S. Eastern Time) to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 22, 2021 (Proxy Statement). The EGM will reconvene on Friday, January 14, 2022, beginning at 5:00 p.m. Irish time (12:00 p.m., U.S. Eastern Time) at 25-28 North Wall Quay, Dublin 1, Ireland.

Over the last 12 months, NBRV stock dropped by -74.10%. The one-year Nabriva Therapeutics plc stock forecast points to a potential upside of 75.66. The average equity rating for NBRV stock is currently 2.70, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $39.00 million, with 50.53 million shares outstanding. Compared to the average trading volume of 762.35K shares, NBRV stock reached a trading volume of 2490952 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Nabriva Therapeutics plc [NBRV]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NBRV shares is $2.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NBRV stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wedbush have made an estimate for Nabriva Therapeutics plc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 19, 2020. The new note on the price target was released on May 02, 2019, representing the official price target for Nabriva Therapeutics plc stock. Previously, the target price had yet another drop from $9 to $7, while H.C. Wainwright kept a Buy rating on NBRV stock.

The Average True Range (ATR) for Nabriva Therapeutics plc is set at 0.06, with the Price to Sales ratio for NBRV stock in the period of the last 12 months amounting to 1.76. The Price to Book ratio for the last quarter was 0.52, with the Price to Cash per share for the same quarter was set at 0.87.

NBRV Stock Performance Analysis:

Nabriva Therapeutics plc [NBRV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.63. With this latest performance, NBRV shares dropped by -16.55% in over the last four-week period, additionally sinking by -50.00% over the last 6 months – not to mention a drop of -74.10% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NBRV stock in for the last two-week period is set at 41.54, with the RSI for the last a single of trading hit 48.84, and the three-weeks RSI is set at 38.55 for Nabriva Therapeutics plc [NBRV]. The present Moving Average for the last 50 days of trading for this stock 0.9022, while it was recorded at 0.5870 for the last single week of trading, and 1.2207 for the last 200 days.

Insight into Nabriva Therapeutics plc Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Nabriva Therapeutics plc [NBRV] shares currently have an operating margin of -1315.42 and a Gross Margin at +68.45. Nabriva Therapeutics plc’s Net Margin is presently recorded at -1382.22.

Return on Total Capital for NBRV is now -113.39, given the latest momentum, and Return on Invested Capital for the company is -121.27. Return on Equity for this stock declined to -186.76, with Return on Assets sitting at -91.10. When it comes to the capital structure of this company, Nabriva Therapeutics plc [NBRV] has a Total Debt to Total Equity ratio set at 23.32. Additionally, NBRV Total Debt to Total Capital is recorded at 18.91, with Total Debt to Total Assets ending up at 13.22. Long-Term Debt to Equity for the company is recorded at 17.16, with the Long-Term Debt to Total Capital now at 13.92.

Reflecting on the efficiency of the workforce at the company, Nabriva Therapeutics plc [NBRV] managed to generate an average of -$965,056 per employee. Receivables Turnover for the company is 1.51 with a Total Asset Turnover recorded at a value of 0.07.Nabriva Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.70 and a Current Ratio set at 4.50.

>> 7 Top Picks for the Post-Pandemic Economy <<

Nabriva Therapeutics plc [NBRV] Insider Position Details

There are presently around $2 million, or 6.80% of NBRV stock, in the hands of institutional investors. The top three institutional holders of NBRV stocks are: FMR LLC with ownership of 1,343,459, which is approximately 0% of the company’s market cap and around 1.40% of the total institutional ownership; FRAZIER MANAGEMENT LLC, holding 425,650 shares of the stock with an approximate value of $0.23 million in NBRV stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $0.12 million in NBRV stock with ownership of nearly -74.938% of the company’s market capitalization.

Positions in Nabriva Therapeutics plc stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 9 institutional holders increased their position in Nabriva Therapeutics plc [NASDAQ:NBRV] by around 263,647 shares. Additionally, 11 investors decreased positions by around 843,912 shares, while 12 investors held positions by with 1,850,060 shares. The mentioned changes placed institutional holdings at 2,957,619 shares, according to the latest SEC report filing. NBRV stock had 3 new institutional investments in for a total of 99,949 shares, while 3 institutional investors sold positions of 54,906 shares during the same period.